HYPER-IGD SYNDROME / MEVALONATE KINASE DEFICIENCY (HIDS/MKD)

Clinical trials for HYPER-IGD SYNDROME / MEVALONATE KINASE DEFICIENCY (HIDS/MKD) explained in plain language.

Never miss a new study

Get alerted when new HYPER-IGD SYNDROME / MEVALONATE KINASE DEFICIENCY (HIDS/MKD) trials appear

Sign up with your email to follow new studies for HYPER-IGD SYNDROME / MEVALONATE KINASE DEFICIENCY (HIDS/MKD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Real-World watch: tracking a drug for rare, debilitating fevers

Disease control Recruiting now

This study aims to monitor the safety and effectiveness of the drug Ilaris (canakinumab) in real-world clinical settings. It will include children and adults with rare hereditary fever syndromes or a form of juvenile arthritis who are already receiving the drug as part of their s…

Matched conditions: HYPER-IGD SYNDROME / MEVALONATE KINASE DEFICIENCY (HIDS/MKD)

Sponsor: Novartis Pharmaceuticals • Aim: Disease control

Last updated Mar 13, 2026 15:06 UTC

HYPER-IGD SYNDROME / MEVALONATE KINASE DEFICIENCY (HIDS/MKD)

Get alerted when new HYPER-IGD SYNDROME / MEVALONATE KINASE DEFICIENCY (HIDS/MKD) trials appear

Real-World watch: tracking a drug for rare, debilitating fevers